PF-07901801 is a Fusion Protein owned by Pfizer, and is involved in 9 clinical trials, of which 6 are ongoing, and 3 are planned.

TTI-622 acts as an antagonist of CD47 and SIRP alpha interaction. CD47 and SIRP alpha interaction generates a negative signal that inhibits macrophage phagocytosis. Macrophages express SIRPalpha glycoprotein that binds to CD47 present on tumor cells. These interactions generate do-not-eat-signal that is used by cancer cells. SIRPaFc is an antibody-like fusion protein that binds to CD47 with high affinity and blocks the activity of CD47 that is up regulated on tumor cells in acute myeloid leukemia and numerous other malignancies. CD47 blockade enhance the potency of anti-cancer antibodies and promote T cell responses to attack cancer cells. The drug candidate alleviates CD47-mediated suppression and promotes anti-tumor responses.

The revenue for PF-07901801 is expected to reach a total of $247m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the PF-07901801 NPV Report.

PF-07901801 was originated by University Health Network and Hospital for Sick Children and is currently owned by Pfizer.

PF-07901801 Overview

TTI-622 is under development for the treatment of relapsed and refractory multiple myeloma, acute myelocytic leukemia, relapsed and refractory lymphoma, indolent non-Hodgkin’s lymphoma, classic Hodgkin’s lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, peripheral T-cell lymphomas (PTCL) and cutaneous T-cell lymphoma, solid tumors and platinum-resistant epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC). It consists of the CD47-binding domain of human SIRP alpha linked to the Fc region of human immunoglobulin IgG4 that acts by targeting CD47. The drug candidate is administered through intravenous route. It is developed based on Stem cell technology. 

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – PF-07901801

Report Segments
  • Innovator
Drug Name
  • PF-07901801
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.